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The antiarrhythmic efficacy and safety of intravenous
recainam, a newly synthesized compound displaying po-
tent class I antiarrhythmic activity, were tested in 10
hospitalized patients with frequent (>30/h) complex ven-
tricular ectopic beats. There were seven men and three
women of average age 57 years (range 21 to 74); five
had ischemic heart disease, three had cardiomyopathy
and two had valvular heart disease. Recainam was given
as a 3.0 mg/kg per 40 min loading infusion followed by
a 0.9 mg/kg per h maintenance infusion over a 24 hour
observation period. Arrhythmia response was assessed
both in the short term (comparing 2 hours before and
1 hour after drug loading) and in the long term (com-
paring 48 hours before drug loading and 23 hours of
maintenance infusion).
The median frequency of total premature ventricular
complexes decreased in the short term by 99.6% (from
392.5 to 1.5/h, p < 0.005) and in the long term by 99.7%
(from 435 to l.3/h , p < 0.01). Repetitive beats were
There is substantial need for the development of versatile
new antiarrhythmic agents, particularly those effective by
both intravenous and oral routes and those effective against
complex ventricular arrhythmias (1-6) . The approach to
antiarrhythmic therapy is currently in a state of flux because
of I) the availabil ity for testing of several new antiarrhyth-
mic agents and other novel therapies , and 2) evolving con-
cepts regarding the risks of arrhythm ias and the need for
therapy (7,8 ). Because current antiarrhythmic therapy is
frequently incompletely effective and often associated with
adverse effects , the need for new agents with increased
efficacy and reduced side effect s by both intravenous and
oral routes is evident in many clinical situations.
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suppressed by a median of 100% both in the short term
(p < 0.006) and during 24 hour infusion (from 80.9 to
Olh , p < 0.003). More than 90% suppression of repetitive
beats occurred in all 10 patients (100%) and more than
90% suppression of total arrhythmias occurred in 9 pa-
tients (90%) during the maintenance period. Electro-
cardiographic PR and QRS intervals increased by 19%
(p < 0.001) and 24% (p < 0.003), respectively, during
therapy, but the JTc interval decreased (p < 0.001).
Plasma recainam concentrationsaveraged 5.2 ± 0.91Lg/mi
after loading and 3.0 ± 0.5 ILg/ml during maintenance
therapy. No adverse symptoms occurred.
In summary, recainam is a promising, highly effi-
cacious and well tolerated agent when administered in-
travenously for short-term and maintenance suppression
of complex ventricular arrhythmias. The efficacy of oral
and intravenous recainam for arrhythmia management
deserves further evaluation .
(J Am Coli Cardiol 1986;8:427-35)
It has now been established that complex ventricular ar-
rhythmias may be associated with an increased risk of mor-
tality in certain clinical situation s, commonly manifested as
sudden death due to ventricular fibrillation (9- 14). Despite
this increased risk, evidence that therapy with standard anti-
arrhythmic agents can substantially reduce risk has not yet
been established (15 ,16 ). However, studies to date have
been fraught with methodologic problem s and have been
limited by antiarrhythmic agents with limited efficacy and
excessive adverse effect s. More ideal agents (17) are thus
required to adequately test the " premature ventricular com-
plex (PVC) hypothesis" of sudden death. In addition , there
is a need for improved therapy of complex ventricular ar-
rhythmias which are associated with significant symptoms
(palpitation, fatigue , dyspnea, light-headedness or syncope,
alone or in combination) .
Recainam (WY-42,362) is a newly synthesized propyl-
urea antiarrhythmic compound (Fig . I) that has shown fa-
vorable pharmacologic effects in animals. suggesting ther-
apeutic potential in humans (18 ,19) . Preliminary results of
0735-1097/86/$3 .50
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Figure I. Molecular structure of recainam (Wy-42,362),N-(2,6-
dimethylphenyl)-N'-[3-(1 -methylethylamino)propyl] urea.
electrophysiologic testing in animal preparations place re-
cainam in antiarrhythmic class I (20,21), but definitive elec-
trophysiologic evaluation in patients has not been reported.
In animal experiments, recainam increases the ventricular
fibrillation threshold and leads to marked suppression of
arrhythmias induced by ouabain, aconitine and coronary
ligation (18). Animal pharmacokinetic data suggest a two-
compartment disposition model, a half-life of about 2 hours
and a substantial renal clearance (19). Initial studies (22-25 )
with single intravenous and oral doses of recainam in hu-
mans have suggested its potential for sustained antiarrhyth-
mic activity. Recainam elimination half-life after a single
intravenous injection was found to be 3.6 hours (23).
On the basis of this promising early testing experience,
we undertook a phase II intravenous study to test the efficacy
and safety of a 24 hour infusion of intravenous recainam in
hospitalized patients with complex ventricular arrhythmias.
Methods
Patient selection criteria. Patients with complex ar-
rhythmias for which therapy was recommended (that is,
those causing symptoms or associated with perceived in-
crease in mortality risk) were candidates for this study. A
frequency of at least 30 premature ventricular complexes
per hour was required, occurring as isolated beats, couplets
or nonsustained ventricular tachycardia (ventricular tachy-
cardia ~ 3 successive beats but < I minute in duration and
Table l. Patient Characteristics
not causing syncope or requiring earlier intervention). Ad-
mission to the coronary care unit and written, informed
consent were required before entry into the study.
Exclusion criteria included age of 75 years or more,
pregnancy, advanced heart failure (New York Heart As-
sociation functional class III or IV), uncontrolled arterial
hypertension (blood pressure > 170/100mm Hg), clinically
advanced hepatic, renal, respiratory' or endocrine disease,
other potentially terminal illness and syncope due to tachy-
arrhythmia. Patients who had had a myocardial infarction
within 3 months were also excluded.
Concurrent antiarrhythmic medications were not al-
lowed, and previousantiarrhythmicdrugs were discontinued
for at least four half-lives before entry. Digitalis was per-
mitted if required for treatment of congestive heart failure.
Patient entry characteristics. Ten patients were entered
into the study (Table I). There were seven men and three
women with an average age of 57 ± 16 years (range 21 to
74). Underlying heart disease included coronary artery dis-
ease in fi ve (all with previous myocardial infarction), car-
diomyopathy in three and valvular heart disease in two. Left
ventricular ejection fraction, determined by either radio-
nuclide or contrast angiographic methods, averaged 0.51 ±
0.16 (range 0.35 to 0.76). Patients were further character-
ized by an average of2 .9 ± 1.7 unsuccessful antiarrhythmic
trials (due to either intolerance or inefficacy) and qualifying
arrhythmias on 24 hour ambulatory (Holter) electrocardio-
gram while receiving no therapy.
Study design. The study was designed as a 24 hour,
open label, acute intervention protocol. The primary end
point was the arrhythmiaresponse over a 23 hour, 20 minute
period (after the 40 minute loading infusion) as compared
with results on the baseline 48 hour recording obtained after
discontinuationof antiarrhythmic therapy and (secondarily)
with those during a 24 hour postdrug washout period. Ef-
fective arrhythmia suppression was defined as an 80% or
Age Cardiac Rhythm Number of Previous
Case (yr) Sex Diagnosis Diagnosis Symptoms Antiarrhythmic Trials
I 54 M CAD PYCs/Cps/runs Dizziness I
2 48 M CAD PYCs/Cps/runs Palpitation 4
3 71 F CM PYCs/Cps/runs Palpitation. dyspnea 5
4 6 1 F CM PYCs/Cps/runs Palpitation 3
5 59 M CAD PYCs/Cps/runs Palpitation 4
6 2 1 M CM PYCs/Cps/runs Light-headedness 0
7 73 M CAD PYCs/Cps/runs Tingl ing in left arm I
8 64 F MYP,MYR PYCs/Cps/runs Palpitation , fatigue 3
9 49 M AI/AS PYCs/Cps/runs Palpitation 4
10 74 M CAD PYCs/Cps/runs Palpitation 4
57.4 ± 15.8 M = 7; CAD = 5; 2.9 ± 1.7
F = 3 CM = 3;
YHD = 2
AliAS = aortic insufficiency/aortic stenosis; CAD = coronary artery disease; CM = cardiomyopathy; Cps = couplets; F = female; M = male;
MYP = mitral valve prolapse; MYR = mitral valve regurgitation; Pyes = premature ventricular complexes; YHD = valvularheart disease ,
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greater reduction in total premature ventricular complex fre-
quency during treatment and a 90% or greater reduction in
repetitive forms, compared with the 48 hour baseline re-
cording (26-28). Patients were hospitalized and, during the
period of drug infusion and washout, were confined to bed
(first 6 hours) or to bed-chair activities (after 6 hours), as
necessitated by the continuous intravenous infusion.
The baseline recording was made after discontinuation
of previous antiarrhythmic therapy for at least four half-
lives. Holter monitor recordings were made on a computer-
based, operator interactive system (Marquette) and analyzed
by a technician unaware of patient characteristics or study
treatment plan: The actual time of the control monitor re-
cording averaged 48.4 ± 4.0 hours (range 44.4 to 59.1).
Total arrhythmia frequency was subdivided into isolated
beats, couplets and beats and events of nonsustained ven-
tricular tachycardia. Ventricular arrhythmias were also doc-
umented directly by trendscription (Trendscriber, American
Optical) during a 2 hour lead-in control period, during initial
drug loading and for 2 hours after the loading infusion.
Trendscription was used to assess short-term drug response
and Holter monitoring was used to assess overall (mainte-
nance) response. Comparisons of Holter monitor (computer-
derived) and trendscription (direct count) frequency assess-
ment of arrhythmias were made for concurrently monitored
times. An excellent correlation was observed, with a cor-
relation coefficient (r) value of 0.97 for logarithmically
transformed values and greater than 0.999 for absolute val-
ues, comparing Holter- and trendscription-derived frequen-
cies. Day to day baseline arrhythmia variability in our group
was assessed by comparison of control day 1 with day 2
frequencies (28).
Recainam dosing regimen. Recainam, 15 mg/kg body
weight, was diluted with 1,000 ml of 0,9% saline solution
and a loading dose of 3.0 mg/kg was given over 40 minutes
by constant infusion using an IVAC 560 pump (IVAC Cor-
poration). After completion of the loading dose, a main-
tenance infusion was initiated at a rate of 0.9 mg/kg per h
for the balance of the 23 hour, 20 minute treatment period.
Clinical observations. Continuous electrocardiographic
observations were made, and interval hard copy electro-
cardiographic assessments were obtained as follows: 121ead
electrocardiogram before drug administration and at 1, 3,
6, 12 and 24 hours, and rhythm strips at a speed of 50 mrn/s
for PR, QRS and QT determinations before study and at 20
and 40 minutes and 1,2,3,4,5,6,8, 10, 12, 14, 18,20,
22 and 24 hours. Simultaneously, a Holter electrocardio-
graphic recording (for the entire 24 hour treatment period)
and initially trendscription, to validate Holter assessment,
for 4 hours and 40 minutes (as defined) were obtained.
Vital signs were measured frequently and recorded before
drug administration (at -2, -1.5, -1 and -0.5 hours)
and at 5,10,20 and 40 minutes and 1, 1.5,2,'3,4,6,8,
10, 12, 18, 24, 36 and 48 hours after initiation of drug
administration. Complete blood count, 20 channel blood
biochemistry survey and urinalysis were obtained before
study and within 3 days of completion of drug treatment.
Blood sampling for drug levels. Blood samples for
determination of recainam plasma concentrations were drawn
before study, at 20 minutes into the loading period, at the
completion of the loading period and at 1, 1.5, 2, 4, 8, 12,
18,24,26,28,30 and 36 hours. Samples were'drawn from
the arm opposite to the infusion site. Blood was collected
in heparinized tubes and centrifuged immediately, and plasma
was separated and frozen. Samples were analyzed by Wyeth
Laboratories. Plasma concentrations of recainam were de-
termined using the method of Kimmel (29), which is a
specific, high pressure liquid chromatographic procedure.
Additional blood samples were drawn at 2, 4, 8, 12 and 24
hours for on-site drug concentration assays for safety reasons
and were analyzed immediately, using the same technique.
Statistical methods. Because arrhythmia frequencies and
frequency responses were not normally distributed, non-
parametric methods were used to establish statistical sig-
nificance (30). The Newman-Keuls method was used in
analyzing significance of variances in data sets (baseline,
treatment, washout) and the Mann-Whitney method was
used for assessing differences between any two of the three
data sets where overall differences were observed. A prob-
ability (p) value of less than 0.005 was regarded as definitive
of a treatment effect. The primary end points, the response
during treatment versus baseline control, were analyzed us-
ing the Wilcoxon rank-sum method for paired samples. The
Student paired t test was applied to assess electrocardio-
graphic interval changes, heart rate and blood pressure changes
during therapy. Arrhythmia frequency is reported as both
median and mean response together with range, also because
of abnormal distributions. A p value of less than 0.05 (two-
tailed hypothesis) was considered significant.
Results
Baseline arrhythmia frequency. The frequency of total
premature ventricular complexes on the baseline 48 hour
Holter recording averaged 794/h (median 435, range 114 to
1,952). A similar frequency of 564/h (median 392.5, range
10.5 to 1,807.5), suggesting stability of arrhythmia occur-
rence, was also observed in these patients during the 2 hour
lead-in control period. The method described by Pratt et al.
(28) was used to measure spontaneous variability between
baseline days 1 and 2 and to describe the reduction in pre-
mature ventricular complexes necessary to exclude spon-
taneous variability as a cause of suppression. The sponta-
neous variability was relatively small. The standard deviation
was equal to 50 premature ventricular complexes/day; 99%
of the total variability in premature ventricular complexes
was due to differences among patients and 1% was due to
spontaneous variability within patients. A reduction of only
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43%, comparing the treatment day with the 2 control days,
was calculated to be sufficient to exclude spontaneous var-
iability, and hence demonstrate drug effect, within 95%
confidence limits. Thus, the validity of our initial indications
of therapeutic success (>80% premature ventricular com-
plex suppression) was confirmed.
Initial Response to Recainam (0 to 1 hour
after loading)
Short-term group response of ventricular arrhyth-
mias (Table 2). Repetitive beats were essentially eliminated
after drug loading (p < 0.006, Wilcoxon). The median
repetitive beat frequency decreased by 100%, from 24.4 to
O/h. Mean repetitive beat suppression was 94%, from a mean
of 39.5 to 2.4/h.
The suppression of total ventricular arrhythmias (total
premature ventricular complexes) was also highly significant
for the first hour after drug loading (p < 0.005, Wilcoxon).
The median total premature ventricular complex frequency
decreased by 99.6%, from 392.5 to 1.5/h. Mean total pre-
mature ventricular complex suppression was 95%, from a
mean of 564 to 29/h.
Individual short-term percent suppression of pre-
mature ventricular complexes. Eight (80%) of the 10
patients had greater than 80% suppression of total premature
ventricular complexes; 5 of these patients showed more than
99% suppression. The median response was 99.2% suppres-
sion. Seven (88%) of the eight patients with repetitive beats
(couplets or runs) during the 2 hour lead-in control period
demonstrated a successful (>90% suppression) response,
with each of these patients showing complete (100%)
suppression.
Arrhythmia Response During Maintenance Therapy
(2 to 24 hours)
Group arrhythmia response to maintenance recainam
infusion (Table 2, Fig. 2 and 3). Suppression of repetitive
beats was highly significant during the maintenance infusion
(p < 0.003, Wilcoxon). All patients had couplets and runs
of tachycardia during the 48 hour baseline Holter recording.
Table 2. Short- and Long-Term Group Response of Ventricular Arrhythmias
Treatment Arrhythmia Frequency/h*
Case
2
3
4
5
6
7
8
9
10
Baseline Arrhythmia Frequency/h*
22 Hours, 20 Minutes
48 Hours 2 Hours I Hour After Loading Maintenance
211.9/198/6.2/0.5 82.5/82.5/0/0 111/0/0 19119/0/0
(98.8/98.8/-/- ) (91190.4/1001100
242.1123114.6/0.5 10.5/10.5/0/0 2/2/0/0 0.2/0.2/0/0
(81/811-/-) (99.9/99.9/100/100)
1,761.5/1,309/66.8/48.6 1,280.5/1,128/39.5/22 111/0/0 004/0.04/0/0
(99.9/99.9/100/100) (97.7/97/100/100)
1,45611711458.9/90.2 538/497/20.5/0 214/214/0/0 1.761.4/1,685117.4/0.36
(60/56.9/100/-) (-21/-885/96.2/99.6)
160.3/138/9.3/0.8 1331125/3.9/0 3/3/0/0 0.04/0.04/0/0
(97.7/97.611 00/-) (100/10011 00/1 00)
114.4/108/2.9/0.04 14.5114.5/0/0 67/43/12/0 2.38/2.3/0.04/0
(-362/-196.5/ i /-) (97.9/97.9/98.611 00)
1,952.4/1,348/232.6/42.1 1,807.5/1,726/30/6.5 0/010/0 0/0/0/0
(100/100/100/100) ( 100/1001100/1 00)
1,171.5/338/62.6/62.8 696.5/637/29/0.5 2/2/0/0 3.7/3.7/0/0
(99.7/99.7/100/100) (99.7/98.911 001100)
5211422/34.9/6.8 828.5/827 .5/0.5/0 0/0/0/0 11/11/0/0
(10011001100/- ) (99.8/99.711 001100)
349.8/278/33.6/0.8 2471193/27/0 0/0/0/0 1.511.5/0/0
(I 00/1 001100/- ) (99.6/99.511 00/100)
*Data are presented (from left to right) as total number of premature ventricular complexes, total number of isolated premature ventricular
complexes, total number of couplets and total number of runs per hour. The percent suppression of the respective arrhythmias is shown below each line
in right-hand columns in parentheses.
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petitive arrhythmias were responsive both in the short term
and during maintenance infusion (97.2% suppression).
Figure 3. Individual response to treatment of total premature
ventricular complex (PVC) frequency. Treatment period is on the
abscissa (similar to Figure 2). Patient numbers as in Figure 2.
Arrhythmia Recurrence During Drug Washout
Twenty-four hour postdrug arrhythmia response (Fig.
2 and 3). The 24 hour postdiscontinuation period was not
a pure "washout" period, as it began with recainam blood
levels that were initially therapeutic. Recainam continued
to be detectable (in low concentrations) for at least 12 hours.
However, premature ventricular complexes generally re-
curred during this 24 hour period. For the entire postdrug
day, premature ventricularcomplex frequency averaged 578/h
(median 427, range 29 to 1,330), which was significantly
greater than during therapy (p < 0.025, Wilcoxon). Re-
petitive beat frequency averaged 195/h (median 47, range
0.1 to 607), which was also a significant increase from
treatment (p < 0.004, Wilcoxon). However, total premature
ventricular complex frequency was significantly different
(lower) in the first postdrug day than in the predrug baseline
study, as might be expected (p < 0.025, Wilcoxon). Re-
petitive beat frequencies also differed significantly in the
two periods (p < 0.04, Wilcoxon).
End-washout arrhythmia recurrence (22 to 24 hours).
Arrhythmia frequencies during the 2 hour end-washout pe-
riod were compared with those for the 2 hour predrug and
I hour postloading responses. This comparison thus con-
stituted a true drug washout comparison. Differences in
frequency among these three periods were highly significant
(p < 0.003, Newman-Keuls). Each control period differed
from the treatment period (p < 0.001 to 0.003, Mann-
Whitney) but not from each other. The average total pre-
I
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Figure 2. Individual patient responses to treatment of frequent
repetitive ventricular complexes (PVCs). Treatment period is on
the abscissa;48hour control, 22 hour, 20 minute drug maintenance
and 24 hour postinfusion periods are presented. Individual patient
entry numbers are indicated to left and right of data points. No
washout data are available for Patient 6.
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The median frequency of couplets decreased by 100%, from
34.2 to O/h during maintenance infusion (mean couplet de-
crease was 98%, from 91.2 to 1.7/h, p < 0.003, Wilcoxon).
The mean number of runs of tachycardia decreased by 99.8%,
from 25.3 to 0.04/h (p < 0.003, Wilcoxon). The median
frequency of all repetitive beats decreased by 100%, from
81 to O/h. Mean repetitive beat suppression was 99%, from
329 to 3.6/h.
Suppression of total arrhythmias was also highly signif-
icant during the maintenance infusion (p < 0.01, Wil-
coxon). The median total premature ventricular complex
frequency decreased by 99.7%, from 435 to 1.3/h. Mean
total premature ventricular complex suppression was 77.5 %,
from a mean of 794 to 179/h.
Individual percent suppression of premature ventric-
ular complexes during maintenance infusion. All 10 pa-
tients (100%) showed a successful response (>90% suppres-
sion) with respect to suppression of repetitive beats. Moreover,
all 10 had essentially 100% suppression of runs, and 8 had
100% suppression of couplets. The other two had greater
than 96% suppression of couplets. Nine patients (90%) re-
sponded at a level of greater than 80% suppression of total
premature ventricular complexes. All nine showed greater
than 90% suppression, and six showed greater than 99%
suppression. The median response was 99.6% suppression.
In one nonresponding patient (Case 4), percent suppres-
sion was -21%. She did, however, show partial (60%)
suppression in the period immediately after drug loading at
a higher recainam plasma concentration (4.95 p,g/ml) than
achieved during maintenance infusion (3.1 p,g/ml). Her re-
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Table 3. Pharmacokinetic Variables in 10 Patients
Measurement
I. Plasma Drug Concentration Cp:Mean ± SO (jLg/ml) Cp:Range (jLg/rril)
A. End-loading (40 minutes)
B. Maintenance (average 2 to 24 hours,
n = 8/patient)
5.2 ± 0.9
3.0 ± 0.5
3.9 to 7.3
2.0 to 4.4
Cp:Mean ± SO (jLg/ml) Median Time (h)
C. At onset of "antiarrhythmic effect"
(2"80% PVC suppression)
O. At escape of "antiarrhythmic effect"
«80% PVC suppression)
4.5 ± 1.6
1.4 ± 1.1
0.67
28 (4 hours after drug
discontinuation)
II. Elimination Half-Life (h) Mean ± SO Median Range
4.8 ± 0.5 4.9 3.3 to 5.1
Cp = plasma concentration; n = number of patients; PVC = premature ventricular complexes.
Figure 4. Comparisons of efficacy (PVC SUPPRESSION) and
plasma drug concentrations (Cp) during the 36 hour observation
period. Time is shown on the abscissa. At time zero, recainam
infusion is begun and at 24 hours, recainam is discontinued. Me-
dian values for individual percent premature ventricular complex
(PVC) suppression are given in the upper curve as open circles
(scaleis givenon theleft ordinate). Corresponding averageplasma
drug concentrations are shown in the lower curve as closed circles
(scale is given on the right ordinate).
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Response of Vital Signs and
Electrocardiographic Intervals
The mean values of vital signs and electrocardiographic
intervals are presented for the control and treatment periods
(averaged) in Table 4. Electrocardiographic PR and QRS
intervals, but not QT intervals, increased. Mean PR interval
increased by 19%, from 188 ± 25 to 224 ± 41 ms (p <
0.001). The mean increase of QRS interval averaged 24%
from a baseline of 95 ± 20 ms to a treatment interval of
118 ± 31 ms (p < 0.003). The heart rate-corrected QT
(QTc) interval was unchanged (425 ± 46 ms at baseline
and 419 ± 47 ms during treatment). The heart rate-corrected
JT interval (JTc), which reflects independent effects on re-
polarization, actually decreased (- 13%) (326 ± 39 ms at
Plasma Drug Kinetic Observations
Plasma drug concentrations (Table 3). Initial recainam
therapy resulted in mean plasma concentrations of
5.2 ± 0.9 p,g/ml (range 3.9 to 7.3) at the end of the 40
minute loading phase. Average levels during maintenance
were lower but remained relatively constant from 2 to 24
hours, averaging 3.0 ± 0.5 p,g/ml (range 2.0 to 4.4).
Plasma elimination half-life. The elimination half-life
of recainam, after 24 hour infusion, averaged 4.8 ± 0.5
hours (range 3.3 to 5.1).
Plasma concentration-response profiles. The median
suppression in arrhythmia frequency for the entire period
of recainam infusion iri all patients is presented together
with the plasma drug concentration in Figure 4. Parallel
trends in plasma drug concentrations and median responses
are noted. A parallel escape in arrhythmia control was as-
sociated with decreasing drug levels in plasma after dis-
continuation of the recainam infusion.
The mean plasma concentration at the onset of antiar-
rhythmic effect (>80% premature ventricular complex
suppression) during drug loading was 4.5 ± 1.6 p,g/ml,
and the median time of onset of suppression was 0.67 hour.
Escape of antiarrhythmic effect (to <80% premature ven-
tricular complex suppression) was observed at a median of
4 hours after discontinuation of treatment when recainam
plasma concentration averaged 1.4 ± 1.1 p,g/ml (range 0.6
to 3.5).
mature ventricular complex frequency was 476/h for the 2
hour end-washout period versus 564/h for the 2 hour baseline
(p = NS, Wilcoxon). This was also the case for repetitive
beat frequencies (76 versus 40/h, respectively, p = NS).
Total and repetitive premature ventricular complex fre-
quencies differed in a highly significant fashion, for the 2
hour end-washout versus the 1 hour treatment periods (p <
0.004, Wilcoxon).
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Control* Recainamt a (absolute) a(%) p Value
Heart rate (beats/min) 70 ± 12 75 ± 10 + 5 P% 0.003
PR (ms) 188 ± 25 224 ± 41 +36 119% 0.001
QRS (ms) 95 ± 20 118 ± 31 +23 124% 0.003
QT (ms) 389 ± 29 368 ± 36 -21 t5% 0.003
QTc (ms) 425 ± 46 419 ± 47 - 6 t 1.4% NS
JT (ms) 295 ± 27 250 ± 18 -45 t 15% 0.001
JTc (ms) 326 ± 39 284 ± 25 -42 t 13% 0.001
SBP (mm Hg) 130 :!: 15 129 :!: 12 - I to.8% NS
DBP (mm Hg) 81 :!: II 86 :!: 8 + 5 16% NS
*Baseline value, 5 minutes before infusion, except supine vital signs, which represent mean of all measurements averaged for each patient (n = 4)
during 2 hour preinfusion period. tValues represent mean of all measurements averaged for each patient (n = 17) during infusion period, 5 minutes to
24 hours, except supine vital signs, averaged only until 2 hours (n = 8). DBP = diastolic blood pressure; NS = not significant; SBP = systolic blood
pressure.
baseline to 284 ± 25 ms during treatment [p < 0.001]).
There was a small associated increase in heart rate during
therapy, from 70 ± 12 (baseline) to 75 ± 10 beats/min
(drug) (p < 0.003).
A slight increase ( +5 mm Hg) was observed in the mean
diastolic blood pressure during the treatment phase, but this
change did not reach significance. Moreover, diastolic blood
pressure did not exceed the defined adverse effect threshold
of 100 mm Hg in any patient.
Adverse reactions. No clinically significant adverse re-
actions attributed to recainam were noted during the infusion
in any patient. No adverse individual electrocardiographic
or hemodynamic changes occurred.
Discussion
Study summary. The results of the present study sug-
gest that recainam is a highly effective new antiarrhythmic
agent. Intravenous recainam rapidly attained and maintained
control of complex ventricular arrhythmias in our group of
10 hospitalized patients. Symptomatic tolerance to recainam
was excellent. Moderate electrocardiographic effects were
noted which suggest a unique electrophysiologic profile.
Initial efficacy of intravenous recainam. The initial
loading regimen of recainam was well tolerated and rapidly
resulted in arrhythmia control. At the end of the 40 minute
loading infusion, 7 (88%) of 8 patients showed complete
suppression of repetitive beats (median response 100%) and
8 (80%) of 10 showed suppression of total premature ven-
tricular complexes (median response, 99.2% suppression).
Sustained antiarrhythmic efficacy and safety during
maintenance infusion. The initial excellent therapeutic re-
sponse was maintained by the maintenance infusion dose.
All 10 patients (100%) noted essentially complete suppres-
sion of repetitive arrhythmias (median response, 100%
suppression). Nine patients showed greater than 90%
suppression of total premature ventricular complexes, and
six had greater than 99% suppression. This degree of
suppression has not been observed with other antiarrhythmic
agents except, perhaps. for selected class IC agents
(4,5,31,32). The response to recainam becomes more im-
pressive in view of the nature of the patients selected for
this study, with most having undergone multiple prior anti-
arrhythmic trials (average 2.9).
Safety and adverse response profile. The tolerance pro-
file for recainam was equally impressive. No adverse sub-
jective effects were noted. In particular, gastrointestinal and
neurologic effects were not observed. Similarly, objective
tolerance was excellent. Minor increases in diastolic blood
pressure in individual patients did not pose a problem and
may reflect volume expansion. No significant overall changes
in blood pressure occurred.
Facilitation of ventricular arrhythmia (proarrhythmia) in
a certain percent of patients is a characteristic of all anti-
arrhythmic drugs so far tested (33), including those with
class IC effects (34,35). In our small study. a proarrhythmic
response was not seen. Patient 4 showed increases in isolated
premature ventricular complexes, but suppression of repet-
itive beats at the lower drug levels achieved during main-
tenance (versus loading) infusion. Greater relative suppres-
sion of repetitive than of isolated premature ventricular
complexes is also characteristic of other antiarrhythmic drugs
(36).
Pharmacokinetic observations. Our observations sug-
gest that recainam plasma concentrations averaging about
3.0 j.Lg/ml (range 2.0 to 4.4) are associated with high levels
of antiarrhythmic efficacy (averaging >90% premature ven-
tricular complex suppression), based on our maintenance
drug infusion experience. The antiarrhythmic effect first
appeared at higher plasma concentrations (4.5 ± 1.6 j.Lg/ml)
during drug loading than those associated with the dis-
appearance of antiarrhythmic effect during drug washout
(1.4 ± 1.1 j.Lg/ml). This observation suggests delayed equil-
ibration of the drug between the plasma compartment and
the tissue compartment representing the site of drug action,
presumably the myocardial cellular or subcellular level. Re-
cainam's average elimination half-life of approximately 5
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hours is similar to that of most available orally effective
antiarrhythmic agents. It thus suggests that convenient oral
dosing of recainam (three or four times a day) is feasible.
Electrocardiographic and hemodynamic effects. Re-
cainam showed moderate effects on the electrocardiogram
but little effect on vital signs during intravenous infusion.
Both PR and QRS intervals increased moderately (19 to
24%) in the absence of prolongation of the QT interval.
These changes are suggestive of a class IC effect (34,37).
Uniquely, however, the JTc interval (heart rate-corrected
JT interval, from the end of the QRS complex to the end
of the T wave), a marker of independent drug effect on
repolarization, actually decreased (by 13%, P < 0.(01), an
effect usually ascribed to class IE agents (37). Decreases
in the JTc interval have not been seen with other class IC
agents such as flecainide or encainide (31,32,34). Because
IC agents such as flecainide occasionally have been asso-
ciated with QT prolongation and proarrhythmia in suscep-
tible patients (34,38), the apparently unique shortening ef-
fects of recainam on the JTc interval may be of particular
value from a safety viewpoint. The occasional mild in-
creases in diastolic blood pressure associated with recainam
infusion have also been seen in carefully monitored studies
of other intravenously active agents, including lidocaine (4),
and may reflect volume loading or minor acute vasocon-
strictor effects in individual patients. However, no overall
change in blood pressure was observed, and no evidence
for heart failure or clinical depression in myocardial function
was noted.
Limitations of the present study. Limitations of our
small study should be kept in mind. This was a short-term
intervention study in a small and select group of patients.
The study was not double-blinded, but Holter recordings
are objective and were read by observers who were unaware
of other patient data. Also, hospitalization of the patients
may have had some effect on arrhythmia frequency. How-
ever, the extremely high degree of antiarrhythmic efficacy
far exceeds the determined day to day variability in our
patient group (only a 43% reduction in premature ventricular
complexes was required to show drug effect within 95%
confidence limits). The degree of placebo response observed
in other similar studies has been low (generally 0 to 30%)
(31,32,39). Adverse proarrhythmic potential, not observed
here, will require assessment in a much larger group of
patients. The lack of adverse hemodynamic effects must be
corroborated by more objective assessments of cardiac func-
tion in larger patient groups, including those with more
depressed ventricular function. Although recainam has been
shown to be bioavailable when administered orally, anti-
arrhythmic efficacy by the oral route will require separate
evaluation.
Conclusions. A clinical protocol for initial and longer
term (24 hours) administration of intravenous recainam, a
new antiarrhythmic drug, was completed. Excellent (un-
surpassed) antiarrhythmic efficacy and tolerance in response
to recainam were observed in a group of hospitalized patients
with complex ventricular ectopic activity. Recainam thus
appears to be a highly promising new drug for intravenous
treatment of complex ventricular arrhythmias and also ap-
pears to be suitable for evaluation of oral therapy.
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